GNH USA

Europe — EMA

Neparvis (Valsartan, Sacubitril)

GNH USA supplies Neparvis (Sacubitril/valsartan), an ARNI for heart failure with reduced ejection fraction and hypertension.

Valsartan, Sacubitril

Request sourcing

1
Pack/s

What is Valsartan, Sacubitril?

Sacubitril/valsartan, the active ingredient in Neparvis, is an Angiotensin receptor neprilysin inhibitor (ARNI) presented as an oral tablet for oral use. It is indicated for the treatment of hypertension and for heart failure with reduced ejection fraction in adult patients. The combination therapy improves cardiovascular outcomes by addressing multiple pathways involved in blood pressure regulation and cardiac remodeling.

GNH USA supplies Neparvis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

What is Valsartan, Sacubitril used for?

Neparvis, an Angiotensin receptor neprilysin inhibitor, is used in cardiovascular conditions that involve blood pressure elevation and cardiac dysfunction. - Heart failure with reduced ejection fraction: improves cardiac function, reduces hospitalization and cardiovascular death. - Hypertension: lowers systolic and diastolic blood pressure in patients with elevated readings. - Cardiovascular risk management: contributes to favorable remodeling and may slow disease progression in patients with combined heart failure and hypertension.

What are the side effects of Valsartan, Sacubitril?

Neparvis may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Low blood pressure (hypotension) - Elevated potassium levels (hyperkalemia) - Cough - Fatigue - Headache

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute kidney injury - Liver enzyme elevation

What precautions apply to Valsartan, Sacubitril?

Neparvis requires careful monitoring and specific safety measures. - Monitor blood pressure: check regularly to avoid hypotension. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check serum potassium: hyperkalemia risk requires periodic monitoring. - Avoid use in pregnancy: potential fetal risk unknown; contraindicated. - Caution with concomitant ACE inhibitors or ARBs: ensure appropriate washout period. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

What does Valsartan, Sacubitril interact with?

Neparvis can interact with several medicines, some of which should be avoided while others need close monitoring.

Major Interactions (Avoid): - ACE inhibitors (including within 36 hours): increased risk of angioedema. - Aliskiren in diabetic patients: heightened renal adverse effects. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Dual neprilysin inhibitors: safety profile not established.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood pressure lowering. - Lithium: potential increase in lithium levels. - Rifampin or other enzyme inducers: may reduce sacubitril/valsartan exposure. - NSAIDs: can impair renal function when combined.

Frequently asked questions

What is Neparvis used for?+
Neparvis contains sacubitril/valsartan and is prescribed for adults with heart failure with reduced ejection fraction and for patients who need additional blood‑pressure control in hypertension. It works as a combined neprilysin inhibitor and angiotensin‑II receptor blocker to improve cardiac function and lower vascular resistance.
How does sacubitril/valsartan work?+
The drug blocks the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release, while simultaneously inhibiting the enzyme neprilysin, which increases circulating natriuretic peptides. The combined effect promotes vasodilation, natriuresis, and reduces pathological cardiac remodeling, leading to better heart‑failure outcomes and lower blood pressure.
What is the usual dose of Neparvis?+
The specific dose of Neparvis is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and concomitant medications. The prescriber will select an appropriate strength and titrate according to therapeutic response and safety monitoring.
Is Neparvis safe during pregnancy or breastfeeding?+
The safety of sacubitril/valsartan in pregnancy has not been established, and it is generally avoided because of potential fetal harm. Limited data exist for breastfeeding; therefore, the drug should be used only if the potential benefit justifies the possible risk to the infant.
How do I order Neparvis from GNH USA?+
To request Neparvis, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Neparvis compare with other heart‑failure medicines?+
Compared with standard ACE inhibitors or ARBs, Neparvis adds neprilysin inhibition, which increases natriuretic peptides and provides additional vasodilatory and anti‑remodeling benefits. Clinical trials have shown lower rates of cardiovascular death and hospitalization versus enalapril, making it a preferred option for many patients with HFrEF.
How should Neparvis be stored and handled?+
Neparvis tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.
How is Neparvis administered?+
Neparvis is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically advised.
What are the most serious risks associated with Neparvis?+
The most serious adverse events include angioedema, severe hypotension, acute kidney injury, and significant hyperkalemia. Patients should be educated to seek immediate medical attention if they develop swelling of the face, lips or throat, a sudden drop in blood pressure, or signs of renal dysfunction.
Who should not use Neparvis?+
Neparvis is contraindicated in patients with a known hypersensitivity to sacubitril, valsartan or any component of the formulation, in those with a history of angioedema related to ACE‑inhibitor or ARB therapy, and in individuals with severe hepatic impairment. Caution is also advised for patients with severe renal impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Valsartan, Sacubitril
Route
Oral Use
Manufacturer
Novartis Europharm Limited
Origin
EU

Related products

Bidcor

Bidcor

Valsartan, Sacubitril

Alter S.A.
EU
Culbista

Culbista

Valsartan, Sacubitril

Stada Arzneimittel Ag
EU
Entresto

Entresto

Valsartan, Sacubitril

Novartis Europharm Limited
EU
Entresto

Entresto

Valsartan, Sacubitril

Novartis Europharm Limited
EU